Prospective Observational Study on Plerixafor After Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Plerixafor is a new CXCR4 inhibitor that is able to improve peripheral blood stem cell (PBSC) mobilization when combined with granulocyte-colony-stimulating factor (G-CSF). The 'on demand' use of plerixafor at the hematopoietic recovery after chemotherapy + G-CSF may be more efficient and cost-effective, but the timing of administration and criteria for patient selection are still under investigation. We collected the data of lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery after chemotherapy + G-CSF. The decision of adding plerixafor was based on PB CD34+ cells at the time of hematopoietic recovery after chemotherapy in patients at their first or subsequent attempt, according to the attending physician choice. The primary endpoint was the assessment of the rate of patients who were able to collect >=2 x 10^6 CD34+/kg.

Detailed Description
-----------------
Plerixafor is a new CXCR4 inhibitor that is able to improve peripheral blood stem cell (PBSC) mobilization when combined with granulocyte-colony-stimulating factor (G-CSF). The 'on demand' use of plerixafor at the hematopoietic recovery after chemotherapy + G-CSF may be more efficient and cost-effective, but the timing of administration and criteria for patient selection are still under investigation. We collected the data of lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery after chemotherapy + G-CSF. The decision of adding plerixafor was based on PB CD34+ cells at the time of hematopoietic recovery after chemotherapy in patients at their first or subsequent attempt, according to the attending physician choice. The primary endpoint was the assessment of the rate of patients who were able to collect >=2 x 10^6 CD34+/kg. Secondary endpoint was the assessment of the rate of patients collecting > 4 x 10^6 CD34+/kg and the median number of apheresis to reach the target.

Official Title
-----------------
Prospective Observational Study on Plerixafor After Chemotherapy

Conditions
-----------------
Lymphoma, Myeloma

Intervention / Treatment
-----------------
* Drug: plerixafor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: lymphoma and myeloma patients treated with plerixafor at the hematopoietic recovery after chemotherapy and G-CSF Exclusion Criteria: patients treated only with G-CSF and plerixafor without chemotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| plerixafor treated patients<br>lymphoma and myeloma patients | Drug: plerixafor<br>* plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy<br>* Other names: Mozobil;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who were able to collect >= 2 x 10^6 CD34+/kg |  | From day 1 to day 25 after mobilizing chemotherapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who were able to collect > 4 x 10^6 CD34+/kg. |  | From day 1 to day 25 after mobilizing chemotherapy |